MRI with Gadolinium-Based Nanoparticles - Nanotechnology for Biomedical Imaging and Diagnostics - page 254

[175] Faucher L, Gossuin Y, Hocq A, Fortin M-A. Impact of agglomeration on the relaxometric
properties of paramagnetic ultra-small gadolinium oxide nanoparticles. nanotechnology
2011; 22 :295103.
[176] park JY, Baek MJ, Choi es, Woo s, Kim JH, Kim TJ, Jung JC, Chae Ks, Chang Y,
Lee GH. paramagnetic ultrasmall gadolinium oxide nanoparticles as advanced T1 MRI
contrast agent: account for large longitudinal relaxivity, optimal particle diameter, and
in vivo T1 MR images. ACs nano 2009; 3 :3663-3669.
[177] Faucher L, Guay-Bégin A-A, Lagueux J, Côté M-F, petitclerc É, Fortin M-A. ultra-
small gadolinium oxide nanoparticles to image brain cancer cells in vivo with MRI.
Contrast Media Mol Imaging 2011; 6 :209-218.
[178] söderlind F, pedersen H, petoral RM Jr, Käll p-O, uvdal K. synthesis and characteri-
sation of Gd2O3 nanocrystals functionalised by organic acids. J Colloid Interf sci
2005; 288 :140-148.
[179] Ahrén M, selegard L, Klasson A, soderlind F, Abrikossova n, skoglund C, Bengtsson
T, engstrom M, Kall p-O, uvdal K. synthesis and characterization of peGylated
Gd2O3 nanoparticles for MRI contrast enhancement. Langmuir 2010; 26 :5753-5762.
[180] Bridot J-L, Faure A-C, Laurent s, Rivière C, Billotey C, Hiba B, Janier M, Josserand V,
Coll J-L, Vander elst L, Muller R, Roux s, perriat p, Tillement O. Hybrid gadolinium
oxide nanoparticles: multimodal contrast agents for in vivo imaging. J Am Chem soc
2007; 129 :5076-5084.
[181] Kryza d, Taleb J, Janier M, Marmuse L, Miladi I, Bonazza p, Louis C, perriat p, Roux
s, Tillement O, Billotey C. Biodistribution study of nanometric hybrid gadolinium
oxide particles as a multimodal speCT/MR/optical imaging and theragnostic agent.
Bioconjug Chem 2011; 22 :1145-1152.
[182] sanchez p, Valero e, Galvez n, dominguez-Vera JM, Marinone M, poletti G, Corti M,
Lascialfari A. MRI relaxation properties of water-soluble apoferritin-encapsulated
gadolinium oxide-hydroxide nanoparticles. dalton Trans 2009; 5 :800-804.
[183] Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, prince MR. nephrogenic
systemic fibrosis: review of 370 biopsy-confirmed cases. JACC Cardiovasc Imaging
2011; 4 :1206-1216.
[184] Kümmerer K, Helmers e. Hospital effluents as a source of gadolinium in the aquatic
environment. environ sci Technol 2000; 34 :573-577.
[185] Rocklage sM, Cacheris Wp, Quay sC, Hahn Fe, Raymond Kn. Manganese (II) n,
n'-dipyridoxylethylenediamine-n, n'-diacetate 5, 5'-bis (phosphate). synthesis and
characterization of a paramagnetic chelate for magnetic resonance imaging enhancement.
Inorg Chem 1989; 28 :477-485.
[186] pan d, schmieder AH, Wickline sA, Lanza GM. Manganese-based MRI contrast
agents: past, present, and future. Tetrahedron 2011; 67 :8431-8444.
[187] Lyon R, Faustino p, Cohen J, Katz A, Mornex F, Colcher d, Baglin C, Koenig s,
Hambright p. Tissue distribution and stability of metalloporphyrin MRI contrast agents.
Magn Reson Med 1987; 4 :24-33.
[188] Zhang Z, He R, Yan K, Guo Q-n, Lu Y-G, Wang X-X, Lei H, Li Z-Y. synthesis and
in vitro and in vivo evaluation of manganese(III) porphyrin-dextran as a novel MRI
contrast agent. Bioorg Med Chem Lett 2009; 19 :6675-6678.
[189] schwert dd, davies JA, Richardson n. Non-Gadolinium-Based MRI Contrast Agents .
Berlin: springer; 2002. p 165-199.